李氏大藥廠(00950.HK)：鹽酸曲唑酮藥片取得國家藥監局藥品註冊證書
格隆匯 12 月 11日丨李氏大藥廠(00950.HK)公告，於2020年12月2日，公司已成功取得中國國家藥品監督管理局就用於治療抑鬱症的《Trittico》®(鹽酸曲唑酮藥片)發出的藥品註冊證書。鹽酸曲唑酮藥片由意大利公司Angelini Pharma製造。
曲唑酮乃一種強效的突觸後血清素5-HT2A受體拮抗劑及一種温和的血清素再攝取抑制劑，原屬抗抑鬱藥SARI(血清素-2拮抗劑╱再攝取抑制劑)組別成員。目前曲唑酮乃唯一一種在全球出售的SARI。目標適應症為伴有或沒有焦慮的抑鬱症。按照超過30年的臨牀試驗，自推出長效釋放配方後，曲唑酮的最佳患者類型是伴有睡眠障礙的抑鬱患者(80%罹患抑鬱症的人士)。
《Trittico》®乃一種長效釋放配方，由AngeliniPharma開發，較任何即時釋放分子的配方有更好的患者依從性。曲唑酮自從原產商AngeliniPharma於一九九零年代初次推出以來，一直獲廣泛處方。《Trittico》®於超過40個國家商業生產，現時亦為用於伴有睡眠障礙的抑鬱患者療程的主要分子。
AngeliniPharma為AngeliniHolding的藥品部門。AngeliniHolding於二十世紀初在意大利創立，擁有近百年曆史，經過多年來的發展，現已成為國際首屈一指的保健集團。時至今日，AngeliniPharma致力於精神健康(包括痛症)、罕見疾病及消費品等範疇，旗下眾多非處方品牌在意大利及海外均享負盛名。
AngeliniPharma乃一間綜合藥業公司，不單坐擁許多領域的主要複方及領先藥品的世界級生產設施及國際營銷業務，旗下更擁有多樣及備受認可的研發項目。與國際公司建立策略夥伴關係能完善及擴充其業務的地理版圖。AngeliniPharma產品的營銷遍及約70個國家，在15國直接經營，僱用超過2,700人，並在超過50個國家透過與頂尖國際藥業集團的策略聯盟商業生產旗下產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
